Wayne Blosser

RET Solvent Front Mutations Mediate Acquired Resistance to Selective RET Inhibition in RET-Driven Malignancies

Benjamin Solomon, Lavinia Tan, Stephen Q. Wong et al. · Journal of Thoracic Oncology · 2020 · 284 citations · Full text

Medicine, Oncology, Pharmacology +17

Aurora A Kinase Inhibition Is Synthetic Lethal with Loss of the <i>RB1</i> Tumor Suppressor Gene

Xueqian Gong, Jian Du, Stephen H. Parsons et al. · Cancer Discovery · 2018 · 233 citations

Life Sciences, Oncology, Pharmacology +17

LY2606368 Causes Replication Catastrophe and Antitumor Effects through CHK1-Dependent Mechanisms

Constance King, H. Bruce Diaz, Samuel McNeely et al. · Molecular Cancer Therapeutics · 2015 · 189 citations · Full text

Life Sciences, Cell Biology, Molecular Biology +17

Characterization and preclinical development of LY2603618: a selective and potent Chk1 inhibitor

Constance King, Henry Diaz, Darlene Barnard et al. · Investigational New Drugs · 2013 · 111 citations

Medicine, Medicinal Chemistry, Pharmacology +11

Broad Spectrum Activity of the Checkpoint Kinase 1 Inhibitor Prexasertib as a Single Agent or Chemopotentiator Across a Range of Preclinical Pediatric Tumor Models

Caitlin D. Lowery, Michele Dowless, Matthew Renschler et al. · Clinical Cancer Research · 2018 · 80 citations · Full text

Medicine, Oncology, Pharmacology +17